Current and historical daily PS Ratio for Amgen Inc (
) from 1990 to Jul 21 2026. The price to sales ratio is calculated by taking the current stock price and dividing it by the trailing twelve-month sales per share. The data is updated every 20 minutes during market hours. The PS ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS ratio is a great valuation tool for evaluating cyclical businesses where the PE ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean. Amgen stock (AMGN) PS ratio as of Jul 21 2026 is 5.33.
More Details
Amgen Inc (AMGN) PS Ratio Chart
Amgen Inc (AMGN) PS Ratio Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1207
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Amgen PS Ratio Historical Data | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date | PS Ratio Data | Date | PS Ratio Data | ||||||
| 2026-07-21 | 5.3 | 5.37 | 5.28 | 5.34 | 2026-05-14 | 4.9 | 4.92 | 4.86 | 4.9 |
| 2026-07-20 | 5.4 | 5.39 | 5.3 | 5.31 | 2026-05-13 | 4.8 | 4.92 | 4.81 | 4.9 |
| 2026-07-17 | 5.5 | 5.51 | 5.27 | 5.34 | 2026-05-12 | 4.8 | 4.93 | 4.8 | 4.9 |
| 2026-07-16 | 5.2 | 5.42 | 5.21 | 5.41 | 2026-05-11 | 4.8 | 4.87 | 4.77 | 4.8 |
| 2026-07-15 | 5.2 | 5.24 | 5.16 | 5.22 | 2026-05-08 | 4.8 | 4.84 | 4.78 | 4.83 |
| 2026-07-14 | 5.2 | 5.23 | 5.17 | 5.18 | 2026-05-07 | 4.8 | 4.83 | 4.77 | 4.79 |
| 2026-07-13 | 5.3 | 5.29 | 5.18 | 5.25 | 2026-05-06 | 4.8 | 4.85 | 4.79 | 4.82 |
| 2026-07-10 | 5.3 | 5.32 | 5.26 | 5.29 | 2026-05-05 | 4.7 | 4.8 | 4.67 | 4.8 |
| 2026-07-09 | 5.4 | 5.37 | 5.26 | 5.3 | 2026-05-04 | 4.8 | 4.76 | 4.69 | 4.72 |
| 2026-07-08 | 5.3 | 5.41 | 5.29 | 5.36 | 2026-05-01 | 4.8 | 4.91 | 4.73 | 4.81 |
| 2026-07-07 | 5.5 | 5.47 | 5.34 | 5.36 | 2026-04-30 | 5.0 | 5.09 | 4.95 | 5.04 |
| 2026-07-06 | 5.4 | 5.45 | 5.24 | 5.34 | 2026-04-29 | 4.9 | 4.94 | 4.86 | 4.92 |
| 2026-07-02 | 5.3 | 5.47 | 5.29 | 5.45 | 2026-04-28 | 5.0 | 5.04 | 4.92 | 4.95 |
| 2026-07-01 | 5.3 | 5.3 | 5.21 | 5.26 | 2026-04-27 | 5.0 | 5.07 | 4.95 | 4.96 |
| 2026-06-30 | 5.3 | 5.29 | 5.2 | 5.28 | 2026-04-24 | 5.0 | 5.06 | 4.99 | 5.02 |
| 2026-06-29 | 5.3 | 5.29 | 5.22 | 5.25 | 2026-04-23 | 5.0 | 5.11 | 5.03 | 5.08 |
| 2026-06-26 | 5.2 | 5.28 | 5.16 | 5.22 | 2026-04-22 | 5.0 | 5.07 | 5 | 5.04 |
| 2026-06-25 | 5.1 | 5.23 | 5.1 | 5.14 | 2026-04-21 | 5.1 | 5.1 | 4.95 | 5.02 |
| 2026-06-24 | 5.1 | 5.16 | 5.04 | 5.12 | 2026-04-20 | 5.2 | 5.2 | 5.1 | 5.1 |
| 2026-06-23 | 5.1 | 5.09 | 5.03 | 5.06 | 2026-04-17 | 5.1 | 5.2 | 5.09 | 5.18 |
| 2026-06-22 | 4.9 | 5.03 | 4.92 | 5.02 | 2026-04-16 | 5.0 | 5.12 | 5.05 | 5.09 |
| 2026-06-18 | 5.0 | 5.03 | 4.87 | 4.92 | 2026-04-15 | 5.1 | 5.14 | 5.01 | 5.07 |
| 2026-06-17 | 5.1 | 5.09 | 4.94 | 4.98 | 2026-04-14 | 5.0 | 5.12 | 5.03 | 5.11 |
| 2026-06-16 | 5.1 | 5.15 | 5.04 | 5.07 | 2026-04-13 | 5.1 | 5.14 | 5.03 | 5.1 |
| 2026-06-15 | 5.2 | 5.22 | 5.09 | 5.11 | 2026-04-10 | 5.2 | 5.21 | 5.1 | 5.11 |
| 2026-06-12 | 5.2 | 5.22 | 5.13 | 5.17 | 2026-04-09 | 5.1 | 5.24 | 5.05 | 5.18 |
| 2026-06-11 | 5.0 | 5.22 | 4.97 | 5.16 | 2026-04-08 | 5.0 | 5.12 | 4.99 | 5.1 |
| 2026-06-10 | 5.0 | 5.08 | 4.92 | 4.92 | 2026-04-07 | 5.0 | 4.98 | 4.88 | 4.95 |
| 2026-06-09 | 5.1 | 5.09 | 4.99 | 5.02 | 2026-04-06 | 5.0 | 5.07 | 4.96 | 4.99 |
| 2026-06-08 | 5.1 | 5.13 | 5.02 | 5.04 | 2026-04-02 | 5.1 | 5.16 | 5.04 | 5.07 |
| 2026-06-05 | 5.1 | 5.19 | 5.06 | 5.09 | 2026-04-01 | 5.2 | 5.2 | 5.12 | 5.15 |
| 2026-06-04 | 5.0 | 5.09 | 4.99 | 5.03 | 2026-03-31 | 5.1 | 5.18 | 5.06 | 5.13 |
| 2026-06-03 | 4.8 | 4.93 | 4.75 | 4.93 | 2026-03-30 | 5.1 | 5.13 | 5.07 | 5.08 |
| 2026-06-02 | 4.8 | 4.8 | 4.7 | 4.78 | 2026-03-27 | 5.2 | 5.24 | 5.13 | 5.14 |
| 2026-06-01 | 4.9 | 4.86 | 4.75 | 4.8 | 2026-03-26 | 5.2 | 5.23 | 5.14 | 5.2 |
| 2026-05-29 | 4.9 | 4.92 | 4.85 | 4.91 | 2026-03-25 | 5.2 | 5.28 | 5.17 | 5.22 |
| 2026-05-28 | 4.9 | 4.92 | 4.87 | 4.9 | 2026-03-24 | 5.1 | 5.2 | 5.1 | 5.13 |
| 2026-05-27 | 5.0 | 4.97 | 4.89 | 4.9 | 2026-03-23 | 5.2 | 5.21 | 5.14 | 5.15 |
| 2026-05-26 | 5.0 | 4.99 | 4.88 | 4.89 | 2026-03-20 | 5.1 | 5.18 | 5.08 | 5.13 |
| 2026-05-22 | 5.0 | 5.01 | 4.93 | 4.94 | 2026-03-19 | 5.2 | 5.25 | 5.13 | 5.16 |
| 2026-05-21 | 4.8 | 4.92 | 4.79 | 4.92 | 2026-03-18 | 5.3 | 5.32 | 5.17 | 5.18 |
| 2026-05-20 | 4.8 | 4.86 | 4.76 | 4.83 | 2026-03-17 | 5.4 | 5.43 | 5.3 | 5.32 |
| 2026-05-19 | 4.7 | 4.84 | 4.68 | 4.82 | 2026-03-16 | 5.4 | 5.47 | 5.37 | 5.4 |
| 2026-05-18 | 4.7 | 4.75 | 4.68 | 4.73 | 2026-03-13 | 5.5 | 5.5 | 5.39 | 5.4 |
| 2026-05-15 | 4.9 | 4.9 | 4.74 | 4.75 | 2026-03-12 | 5.5 | 5.53 | 5.42 | 5.42 |
Amgen Inc (AMGN) PS Ratio Comparison
| Company | Market Cap(Mil) | PS Ratio |
|---|
Business Description
Business Description
Amgen Inc
NAICS : 325412
SIC : 2834
ISIN : US0311621009
Share Class Description:
AMGN: Ordinary SharesTotal Employee Number:
31,500Compare
Compare
Traded in other countries / regions
AMGN.USAAMGN.CanadaAMGN.Argentina0R0T.UKAMGN34.BrazilAMG.GermanyAMGN.Austria1AMGN.ItalyAMG N.MexicoAMGN.Chile04332.Hong Kong Index Membership
Dow 30S&P 500NASDAQ 100Russell 1000Russell 3000MSCI World Index IPO Date
1983-06-17Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers